Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-day intravaginal oxybutynin feasibility study using the MedRing OAB system
NL-OMON60446Phase 1Completed
- Sponsor
- LiGalli
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of oxybutynin in overactive bladder (OAB), sponsored by LiGalli. Started Feb 2024; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON60446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60446.